SpyGlass Pharma, Inc. (SGP)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
SpyGlass Pharma, Inc. has not issued a press release in this window.
SEC filings
All filings →SpyGlass Pharma, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →SpyGlass Pharma, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for SpyGlass Pharma, Inc. in this window.
People at SpyGlass Pharma, Inc.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for SpyGlass Pharma, Inc..